SCIENTIFIC REPORTS

OPEN

A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease

Received: 05 February 2016

Accepted: 04 May 2016

Published: 07 June 2016

Haochen Liu¹, Xiaoting Zhou¹, Hao Jiang¹, Hua He¹, Xiaoquan Liu¹ & Alzheimer's Disease Neuroimaging Initiative**

Mild cognitive impairment (MCI) is a precursor phase of Alzheimer's disease (AD). As current treatments may be effective only at the early stages of AD, it is important to track MCI patients who will convert to AD. The aim of this study is to develop a high performance semi-mechanism based approach to predict the conversion from MCI to AD and improve our understanding of MCI-to-AD conversion mechanism. First, analysis of variance (ANOVA) test and lasso regression are employed to identify the markers related to the conversion. Then the Bayesian network based on selected markers is established to predict MCI-to-AD conversion. The structure of Bayesian network suggests that the conversion may start with fibrin clot formation, verbal memory impairment, eating pattern changing and hyperinsulinemia. The Bayesian network achieves a high 10-fold cross-validated prediction performance with 96% accuracy, 95% sensitivity, 65% specificity, area under the receiver operating characteristic curve of 0.82 on data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The semi-mechanism based approach provides not only high prediction performance but also clues of mechanism for MCI-to-AD conversion.

Alzheimer's disease (AD), the most common form of dementia, is characterized by progressive neurodegenerative disorder¹. 36 million people worldwide are affected by AD and the number is expected to almost triple by 2050². Many evidences indicate that AD has a years to decade preclinical period followed by a precursor phase termed as mild cognitive impairment (MCI)³. As new treatments are likely to be most effective at the early stages of AD, it is greatly urgent to track patients with MCI who will develop AD^{4,5}.

Several sensitive imaging modalities such as structural magnetic resonance imaging (MRI) and positron emission tomography (PET) have been developed⁵. A number of previous researches have reported that MRI biomarkers can be used to predict the probability of conversion^{6–8}. However, because some of structural changes may not be detected at visual inspection until MCI patients have converted to AD, predictions using MRI biomarkers only may not be accurate enough for application in the routine clinical setting or clinical drug trials^{3,5}. Previous researches show that combined markers such as MRI and cerebrospinal fluid (CSF) biomarkers can improve the prediction accuracy^{5,9}. But CSF sample collection requires lumbar puncture which is too invasive to be used as a routine clinical examination. As damage to the blood-brain barrier may occur in AD, this may increase movement of proteins between the brain and the blood¹⁰. It is therefore possible that AD and its precursor, MCI, may be associated with the variation of biomarkers detectable in plasma¹¹. Recent work has demonstrated the possibility of predicting MCI-to-AD conversion based on plasma markers¹². In addition, blood sample is more accessible and suitable for repeated collecting. These make plasma-based biomarkers promising for prediction of conversion from MCI to AD.

While the highly sensitive markers are beneficial on the conversion prediction, advanced machine learning methods can further improve the reliability of approaches. Machine learning is the study of algorithms and

¹Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, China.

**A comprehensive list of consortium members appears at the end of the paper. Correspondence and requests for materials should be addressed to H.H. (email: huahe827@163.com) or X.L. (email: lxq@cpu.edu.cn)

computational techniques that use previous examples in the form of multivariate datasets to help make future predictions¹³. A number of machine learning methods such as support vector machines (SVM) and logistic regression (LR) have been used to predict the conversion from MCI to AD^{5,8}. Compared with the traditional data-driven machine learning methods, Bayesian network has unique advantages that it can quantify the causal relationships between the markers, visualize these relationships by the structure of network, and conduct the prediction task based on the causal relationships¹⁴. These attractive characteristics make Bayesian network a semi-mechanism method. On one hand, the semi-mechanism nature of Bayesian network can improve our understanding of conversion mechanism. On the other hand, because of the complex etiology and multiple pathogenesis of AD, the conversion from MCI to AD is affected by many uncertain factors which makes its prediction a complicated issue¹⁵. Bayesian network is especially well-suited to handle the intricacies of the prediction because it is designed for representing stochastic events and conducting prediction tasks under uncertainty^{16,17}.

Lots of lectures based on data-driven methods, such as neural network with self-organizing maps (SOM), are focused on improving the classification performance and they have showed good performance in the diagnosis task. However, the contribution of these methods on improving our understanding of MCI-to-AD conversion mechanism is limited. As the semi-mechanism nature of Bayesian network can provide causal relationships of markers, this paper proposes a semi-mechanism method based on the combination of Bayesian network and lasso regression for not only the high performance of MCI-to-AD conversion prediction but also improving our understanding the mechanism of the conversion. The data from Alzheimer's Disease Neuroimaging Initiative (ADNI) is used to develop the model. However, ADNI contains more than 500 biomarkers (including MRI markers and plasma markers), many of which may not relate to MCI-to-AD conversion. Irrelevant biomarkers may interfere the causal relationships identification and reduce the performance of prediction method. Therefore, biomarkers selection should be performed before the conversion prediction. In this study, lasso regression is proposed to conduct the markers selection, which combines variable selection with an efficient computational procedure¹⁸. Previous works have shown that lasso regression can enhance the prediction performance of models based on high dimension data sets^{19–21}. As such, the combination of Bayesian network and lasso regression is proposed not only to conduct the prediction task but also to improve understanding of the AD-to-MCI conversion mechanism. Moreover, after the conversion probability is calculated, a subgroup analysis is performed for comparing the network disruption of high-risk patients and low-risk patients.

Results

Biomarkers selection. In this section, the process of biomarkers selection is described. The dataset used in this study contains 518 biomarkers (328 MRI markers and 190 plasma markers). 45 biomarkers (1 MRI marker and 44 plasma markers) are deleted during data checking due to too many missing entries. 75 biomarkers (57 MRI markers and 18 plasma markers) with significant difference between converters and non-converters are identified by ANOVA test. 34 biomarkers (25 MRI markers and 9 plasma markers) related to Alzheimer's disease assessment scale (ADAS-cog) are selected by lasso regression. 7 biomarkers (5 MRI markers and 2 plasma markers) are eliminated during Bayesian network structure learning because they fail to connect to the Bayesian network. In addition, as 2 MRI markers are labeled as “unknown”, they are also eliminated. Finally, 25 biomarkers (18 MRI markers and 7 plasma markers) are selected for conversion prediction. The process of biomarkers identification is summarized in Fig. 1. The list of selected biomarkers is shown in Table 1.

Structure and performance of Bayesian network. In this section, we present the results of Bayesian structure learning and the performance of conversion prediction. The Bayesian network structure obtained by max-min hill-climbing (MMHC) is given in Fig. 2. It contains 26 nodes and 43 arcs.

In order to evaluate the performance of Bayesian network, a 10-fold cross-validation is performed to estimate its accuracy, sensitivity and specificity. Furthermore, the performance of Bayesian network is compared to the performances of linear discriminant analysis (LDA) and SOM. The performances of all these methods are evaluated by 10-fold cross-validation. The results are given in Fig. 3. The Fig. 3A shows that the accuracy and sensitivity of Bayesian network are higher than those of LDA and SOM with markers selection. In Fig. 3B, the area under receiver operating characteristic curve (AUC-ROC) of Bayesian network is much higher than that of LDA and SOM with marker selection. Moreover, to evaluate the performance of markers selection, we apply SOM and Bayesian network with or without markers selection and compare their performances. With markers selection, the classification performances of both SOM and Bayesian network are improved.

Network disruption profile. According to the result of Bayesian network, a group of highest conversion probability patients (high-risk group, $n = 11$) and a group of lowest conversion probability patients (low-risk group, $n = 48$) are drawn from the dataset. 11 biomarkers have significant difference ($P < 0.05$, ANOVA test) between high-risk group and low risk group. The mini network balance map Fig. 4A) shows that the high-risk group may suffer from more severe network disruption than the low risk group. The network disruption parameters coincide with the mini network balance map. Parameters U and φ increase significantly in high risk group ($P < 0.01$, ANOVA test, shown in Fig. 4B) which may suggest that patients with greater U and φ may have higher conversion risk.

Discussion

In this study, we propose a semi-mechanism based Bayesian network to predict the conversion from MCI to AD. The proposed method has two contributions. Firstly, the proposed approach achieves relative high prediction performance. Secondly, as the Bayesian network can learn the causal relationships among biomarkers from the database, these causal relationships can provide some more insight into the mechanism of MCI-to-AD conversion.

Figure 1. The process of markers selection.

The proposed model is compared to previous researches based on data-driven methods (Table 2). Comparing with LDA and SOM, Bayesian network has higher accuracy and sensitivity with markers selection. The high sensitivity of Bayesian network may lie in two points. On one hand, the semi-mechanism nature of Bayesian network may provide higher performance because it can learn causal relationships from data and combine these knowledge and data to conduct the prediction task²². On the other hand, plasma markers may be highly sensitive in conversion prediction¹². Though the data-driven methods also achieved high performance, the Bayesian network still has its unique advantage. The structure of Bayesian network may contain the causal relationships of markers which makes it a semi-mechanism method and provide more information beyond the performance of classification.

In addition, with markers selection, the classification performance of Bayesian network is improved. It suggests that Bayesian network should work with an appropriate marker selection strategy. In another words, without markers selection, Bayesian network may produce false positive causal relationships which may not only decrease the performance but also mislead the MCI-to-AD conversion mechanism investigation. Therefore, combining Bayesian network and lasso marker selection strategy is very helpful in improving understanding the conversion mechanism and classification performance.

The semi-mechanism nature of Bayesian network is beneficial on investigating the mechanism of conversion. Structure of Bayesian network shows that 6 markers including volume of left middle temporal, cortical thickness average of right entorhinal, volume of right inferior temporal, AGRP, c-peptide, and fibrinogen may be related to the conversion directly. Our result, that destruction of entorhinal is associated with MCI-to-AD conversion, is consistent with previous research²³. Previous researches had also reported the variations of temporal, c-peptide level, and fibrinogen level in AD patients^{19,24,25}. However, our results suggest that these changes may have happened at MCI stage. It indicates that the conversion from MCI to AD may start with destruction of temporal, entorhinal, increased level of AGRP, c-peptide, and fibrin²⁵.

Number	Abbreviation	Marker	Source
1	ST109TS	Cortical Thickness SD of Right Posterior Cingulate	MRI
2	ST111CV	Volume of Right Precuneus	MRI
3	ST114TA	Cortical Thickness Average of Right Rostral Middle Frontal	MRI
4	ST11SV	Volume (WM Parcellation) of Left Accumbens Area	MRI
5	ST121TA	Cortical Thickness Average of Right Transverse Temporal	MRI
6	ST30SV	Volume (WM Parcellation) of Left Inferior Lateral Ventricle	MRI
7	ST31TA	Cortical Thickness Average of Left Inferior Parietal	MRI
8	ST40CV	Volume (Cortical Parcellation) of Left Middle Temporal	MRI
9	ST49TA	Cortical Thickness Average of Left Postcentral	MRI
10	ST52CV	Volume (Cortical Parcellation) of Left Precuneus	MRI
11	ST56CV	Volume (Cortical Parcellation) of Left Superior Frontal	MRI
12	ST70SV	Volume (WM Parcellation) of Right Accumbens Area	MRI
13	ST72CV	Volume (Cortical Parcellation) of superior temporal sulcus	MRI
14	ST83CV	Volume (Cortical Parcellation) of Right Entorhinal	MRI
15	ST83TA	Cortical Thickness Average of Right Entorhinal	MRI
16	ST88SV	Volume (WM Parcellation) of Right Hippocampus	MRI
17	ST91CV	Volume (Cortical Parcellation) of Right Inferior Temporal	MRI
18	ST99CV	Volume (Cortical Parcellation) of Right Middle Temporal	MRI
19	AGRP	Agouti-Related Protein (AGRP)	Plasma
20	–	C-peptide	Plasma
21	CRP	C-Reactive Protein (CRP)	Plasma
22	FGF-4	Fibroblast Growth Factor 4 (FGF-4)	Plasma
23	–	Fibrinogen	Plasma
24	–	Insulin (uIU/mL)	Plasma
25	MMP-10	Matrix Metalloproteinase-10 (MMP-10)	Plasma
26	–	Whether patients converts to AD or not	–

Table 1. List of selected markers.

Figure 2. The structure of Bayesian network. It contains 26 nodes and 43 arcs. The nodes in order are: ST109TS, ST111CV, ST114TA, ST11SV, ST121TA, ST30SV, ST31TA, ST40CV, ST49TA, ST52CV, ST56CV, ST70SV, ST72CV, ST83CV, ST83TA, ST88SV, ST91CV, ST99CV, AGRP, C-peptide, CRP, FGF-4, Fibrinogen, Insulin, MMP-10, and “Whether patients converts to AD or not”.

Bayesian network identifies the variations of above six markers caused by MCI-to-AD conversion directly. But some of these changings may not be the key factors in the conversion. Therefore a reanalysis based on the

Figure 3. The performance of five different conversion prediction models. (A) The receiver operating characteristic (ROC) curve of Linear discriminant analysis (LDA), self-organizing map (SOM) (with or without markers selection) and Bayesian network (with or without markers selection). (B) The performance of LDA, SOM (with or without markers selection) and Bayesian network (with or without selection) measured by three parameters: accuracy, sensitivity, specificity. All these parameters are evaluated by 10-fold cross-validation.

Figure 4. (A) Network disruption analysis of markers with significant difference between high-risk group and low-risk group. In normal state, the shape of radar graph is a regular polygon. With the shape deformation, the difference from normal state gets greater. (B) Box plot of parameters U, K, and ϕ . If the value of disruption parameters U and ϕ is beyond the horizontal lines in figures, the patient may have more conversion risk. * $P < 0.05$, ** $P < 0.01$ vs low risk group.

Research	Included components	Sample size	Results
Bayesian network (with marker selection, this study)	MRI + plasma	365	Accuracy = 96%
			Sensitivity = 95%
			Specificity = 63%
			AUC = 0.82
Bayesian network (without marker selection, this study)	MRI + plasma	365	Accuracy = 70%
			Sensitivity = 30%
			Specificity = 70%
			AUC = 0.56
neural network with self-organizing maps (SOM) (with marker selection, this study)	MRI + plasma	365	Accuracy = 77%
			Sensitivity = 55%
			Specificity = 73%
			AUC = 0.72
SOM (without marker selection, this study)	MRI + plasma	365	Accuracy = 71%
			Sensitivity = 48%
			Specificity = 55%
			AUC = 0.63
Linear discriminant analysis (LDA) (with marker selection, this study)	MRI + plasma	365	Accuracy = 63%
			Sensitivity = 57%
			Specificity = 66%
			AUC = 0.66
Linear discriminant analysis (LDA) ⁸	MRI	405	Accuracy = 68%
			Sensitivity = 67%
			Specificity = 69%
Gularized logistic regression (RLR) ⁴²	CSF	335	Accuracy = 53%
			Sensitivity = 31%
			Specificity = 73%
Domain transfer learning ⁴³	PET	99	Accuracy = 71%
			Sensitivity = 76%
			Specificity = 67%
			AUC = 0.74
Multi-task Linear Programming Discriminant (MLPD) ⁴⁴	MRI + PET	202	Accuracy = 67%
			Sensitivity = 68%
			Specificity = 67%
Logistic regression models ⁵	MRI + PET + CSF	97	Accuracy = 72%
low density separation (LDS) ⁴⁰	MRI + age + cognitive score	394	Accuracy = 82%
			Sensitivity = 87%
			Specificity = 74%
			AUC = 0.9

Table 2. Comparisons to other methods.

results of Bayesian network is performed to identify the major factors. The subgroups network disruption profile suggests that the progress MCI patient may suffer from more severe network disruption than stable MCI patients. Network disruption may be related to the marker panel including 11 markers. The six markers identified by Bayesian network and marker panel related network disruption share three markers: Cortical Thickness of Entorhinal, Volume of Temporal and AGRP. These three markers may be the key factors in the conversion. In other word, they might be attributed to the warming signals of conversion. Previous researches showed that the destruction of entorhinal and temporal is associated with verbal memory impairment and verbal memory impairment might be the warming indicator of MCI-to-AD conversion²⁶. In addition, clinical researches have reported that AD patients have greater preference for high-fat and sweet food than normal groups. However, our results suggested that such change in eating pattern may have happened at MCI stage^{27,28}, as the elevated level of AGRP, an orexigenic peptide, in high-risk patients may increase the preference for a high fat diet²⁹.

The crosstalk between cerebral destruction and plasma markers alteration revealed by Bayesian network can provide more clues for the mechanism of conversion. The crosstalk between C-peptide and cerebral destruction may play a vital role in the MCI-to-AD conversion. C-peptide is a measure of insulin secretion. Elevated C-peptide level represents high peripheral insulin secretion. It is reported that high peripheral insulin secretion can increase the risk of AD. Because high level peripheral insulin secretion impairs amyloid clearance by inhibiting brain insulin production which is a beneficial effect on amyloid clearance³⁰. Bayesian network suggests that C-peptide may be related to the destruction of middle temporal, entorhinal, and inferior temporal. It suggests that

	MCI	Converters	Non-Converters
Number	316	99	217
Age	74.68 ± 7.23	74.72 ± 7.25	74.67 ± 7.25
Gender (male/female)	206/110	58/41	148/69
ADAS-cog (85 points total)	18.63 ± 6.36	22.36 ± 4.56	16.94 ± 4.84

Table 3. Subjects demographic information.

amyloid may mainly aggregate in the above three regions at the MCI stage which may aggravate their damage. As all above three regions are involved in verbal memory, high level of C-peptide may impair to verbal memory which was confirmed by previous works^{26,31–33}.

In summary, the analysis of Bayesian network shows that the conversion from MCI to AD may start with multiple pathological changes such as verbal memory impairment, vascular abnormalities, hyperinsulinemia and eating pattern change. In this study, a high performance semi-mechanism based approach is developed to predict the conversion from MCI to AD by combining MRI and plasma markers. The semi-mechanism based approach provides not only high performance prediction but also more insight into the mechanism of conversion from MCI to AD.

Subject and Method

Subject. *Patients.* In this study, the following criteria are used to select subjects for model developing:

- Patients with baseline MRI scan records
- Patients with baseline plasma-based biomarker data
- Patients with baseline ADAS-cog scores
- Patients with MCI due to Alzheimer's disease
- Patients with diagnosis records which can be used to determine whether they convert from MCI to AD in 18 months

Finally, a data set with complete imaging, plasma-based biomarkers, ADAS data is drawn from ADNI including 316 MCI patients (99 converters and 217 non-converters). The demographic information of subjects is given in Table 3.

Imaging biomarkers. Imaging data in this study is obtained from dataset UCSF—Cross-Sectional FreeSurfer (FreeSurfer Version 4.3). The dataset is available at <https://ida.loni.usc.edu/pages/access/studyData.jsp>. In this dataset, all scans were acquired on 1.5 T MRI scanners. The imaging data were processed and analyzed with FreeSurfer 4.3 by the UCSF team. The dataset includes 328 MRI biomarkers which can be grouped into 5 categories: average cortical thickness, standard deviation in cortical thickness, the volumes of cortical parcellations (based on regions of interest automatically segmented in the cortex), the volumes of specific white matter parcellations, and the total surface area of the cortex. Details of the analysis procedure are available at <http://adni.loni.ucla.edu/research/mri-post-processing/>.

Plasma-based biomarkers. The plasma-based biomarker data is obtained from dataset Biomarkers Consortium Plasma Proteomics Project RBM multiplex data. The data is available at <https://ida.loni.usc.edu/pages/access/studyData.jsp>. The data was acquired by analyzing a subset of plasma samples from the ADNI cohort in a 190 analyte multiplex immunoassay panel. The panel, referred to as the human discovery map, was developed on the Luminex xMAP platform by Rules-Based Medicine (RBM) to contain proteins previously reported in the literature to be altered as a result of cancer, cardiovascular disease, metabolic disorders and inflammation. Details of the assay technology and validation has been described elsewhere (http://adni.loni.ucla.edu/wp-content/uploads/2010/11/BC_Plasma_Proteomics_Data_Primer.pdf).

Method. Considering that ADNI contains more than 500 biomarkers, it is essential to select the more predictive biomarkers to obtain a parsimonious model and avoid the classifier suffering overfitting. Then the Bayesian network is established based on the causal relationships among selected markers for predicting the AD-to-MCI conversion. Finally, a reanalysis of Bayesian network results is performed to profile the network disruption of the patients with highest probability of converting to AD and those with lowest probability. The framework is summarized in Fig. 5.

Biomarkers selection. Biomarkers selection includes two stages. At the first stage, ANOVA test is employed to screen biomarkers with significant difference ($P < 0.05$) between converters and non-converters. At the second stage, lasso regression is used to filter biomarkers related to ADAS-cog from the selected biomarkers at the first stage.

Lasso regression is a popular technique for feature selection which can continuously shrinks coefficients³⁴. It drops biomarkers by shrinking some of coefficients to zero. In this study, a Least Angle Regression (LARS) algorithm is used to solve lasso³⁵.

Figure 5. The machine learning framework.

Bayesian network. Considering that the causal relationships among the selected markers may remain unknown, a Bayesian network structure learning algorithm termed as the max-min hill-climbing (MMHC) is employed to learn the causal relationships among the selected markers. MMHC algorithm is a hybrid method, using concepts and techniques from both constraint-based approaches and score-based approaches, which can achieve high quality in structure learning³⁶. After the Bayesian network is learned from data, the most popular Bayesian network inference algorithm named junction tree is employed to acquire the conversion prediction³⁷.

Model evaluation. In this study, the receiver operating characteristic (ROC) curve is used to evaluate the performance of Bayesian network. The ROC, which has become established as an important tool for classifier evaluation, is a graph of true positive rate (TPR) against false positive rate (FPR) at various operating points as a decision threshold³⁸. The area under the ROC curve (AUC) is a measure of predictive ability³⁹. Moreover, three parameters termed as accuracy (number of correctly classified samples divided by the total number of samples), sensitivity (the number of correctly classified converters divided by the total number of converters) and specificity (the number of correctly classified non-converters divided by the total number of non-converters) are calculated and evaluated by 10-fold cross-validation for a further measurement for the model performance⁴⁰.

Network disruption analysis. To get more insight into the mechanism of the conversion, a reanalysis of Bayesian network results is performed using a mathematic method for evaluating the disruption of biology network which was proposed in our previous research⁴¹. In this study, subjects are divided into two subgroups high risk group and low risk group according to the results of Bayesian network and a mini network balance model is developed to evaluate the network disruption for both high-risk group and low-risk group. The network disruption comparison between these two subgroups may provide more insight into the mechanism of AD-to-MCI conversion.

The mini network balance model contains three parameters U , K , and φ . U is response to both consistency variation and inconsistency variation comprehensively. K responds to multi-marker consistency variation. φ is response to the multi-marker inconsistency variation. These three parameters can be calculated as below:

$$K = \frac{|V_{risk}|}{|V_{normal}|} \quad (1)$$

$$\varphi = \cos^{-1} \frac{V_{risk} \cdot V_{normal}}{|V_{risk}| |V_{normal}|} \quad (2)$$

$$U = \sqrt{(V_{risk} - V_{normal})(V_{risk} - V_{normal})^T}. \quad (3)$$

Let V_{risk} be the state vector of patients with conversion risk and V_{normal} be the state vector of normal control group.

References

- Trzepacz, P. T. *et al.* Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. *Neurobiology of aging* **35**, 143–151, doi: 10.1016/j.neurobiolaging.2013.06.018 (2014).
- Barnes, D. E. & Yaffe, K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *The Lancet Neurology* **10**, 819–828, doi: [http://dx.doi.org/10.1016/S1474-4422\(11\)70072-2](http://dx.doi.org/10.1016/S1474-4422(11)70072-2) (2011).
- Petrella, J. R., Coleman, R. E. & Doraiswamy, P. M. Neuroimaging and early diagnosis of Alzheimer disease: A look to the future. *Radiology* **226**, 315–336, doi: 10.1148/radiol.2262011600 (2003).
- Drago, V. *et al.* Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. *Journal of Alzheimer's disease JAD* **26** Suppl 3, 159–199, doi: 10.3233/JAD-2011-0043 (2011).
- Shaffer, J. L. *et al.* Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. *Radiology* **266**, 583–591 (2013).
- Cho, Y., Seong, J.-K., Jeong, Y. & Shin, S. Y. Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data. *NeuroImage* **59**, 2217–2230, doi: <http://dx.doi.org/10.1016/j.neuroimage.2011.09.085> (2012).
- Coupé, P., Eskildsen, S. F., Manjón, J. V., Fonov, V. S. & Collins, D. L. Simultaneous segmentation and grading of anatomical structures for patient's classification: Application to Alzheimer's disease. *NeuroImage* **59**, 3736–3747, doi: <http://dx.doi.org/10.1016/j.neuroimage.2011.10.080> (2012).
- Wolz, R. *et al.* Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. *PloS one* **6**, e25446 (2011).
- Eckerstrom, C. *et al.* Multimodal Prediction of Dementia with up to 10 Years Follow Up: The Gothenburg MCI Study. *Journal Of Alzheimers Disease* **44**, 205–214, doi: 10.3233/jad-141053 (2015).
- Hye, A. *et al.* Proteome-based plasma biomarkers for Alzheimer's disease. *Brain* **129**, 3042–3050, doi: 10.1093/brain/awl279 (2006).
- Jayasena, T. *et al.* Upregulation of glycolytic enzymes, mitochondrial dysfunction and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma. *PLoS One* **10**, e0116092, doi: 10.1371/journal.pone.0116092 (2015).
- Hye, A. *et al.* Plasma proteins predict conversion to dementia from prodromal disease. *Alzheimer's & Dementia* **10**, 799–807.e792, doi: 10.1016/j.jalz.2014.05.1749 (2014).
- Challis, E. *et al.* Gaussian process classification of Alzheimer's disease and mild cognitive impairment from resting-state fMRI. *NeuroImage* **112**, 232–243, doi: 10.1016/j.neuroimage.2015.02.037 (2015).
- Xu, B. G. Intelligent fault inference for rotating flexible rotors using Bayesian belief network. *Expert Systems with Applications* **39**, 816–822, doi: 10.1016/j.eswa.2011.07.079 (2012).
- Gomez-Ramirez, J. & Wu, J. Network-based biomarkers in Alzheimer's disease: review and future directions. *Frontiers in aging neuroscience* **6**, 12, doi: 10.3389/fnagi.2014.00012 (2014).
- Bandyopadhyay, S. *et al.* Data mining for censored time-to-event data: a Bayesian network model for predicting cardiovascular risk from electronic health record data. *Data Mining and Knowledge Discovery* **29**, 1033–1069, doi: 10.1007/s10618-014-0386-6 (2014).
- Wang, K. J., Makond, B. & Wang, K. M. Modeling and predicting the occurrence of brain metastasis from lung cancer by Bayesian network: a case study of Taiwan. *Computers in biology and medicine* **47**, 147–160, doi: 10.1016/j.combiomed.2014.02.002 (2014).
- Meinshausen, N. Relaxed Lasso. *Computational Statistics & Data Analysis* **52**, 374–393, doi: 10.1016/j.csda.2006.12.019 (2007).
- Zou, H. The adaptive lasso and its oracle properties. *Journal of the American statistical association* **101**, 1418–1429 (2006).
- Li, Z. & Sillanpaa, M. J. Overview of LASSO-related penalized regression methods for quantitative trait mapping and genomic selection. *TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik* **125**, 419–435, doi: 10.1007/s00122-012-1892-9 (2012).
- Ogutu, J. O. & Piepho, H.-P. Regularized group regression methods for genomic prediction: Bridge, MCP, SCAD, group bridge, group lasso, sparse group lasso, group MCP and group SCAD. *BMC Proceedings* **8**, 1–9, doi: 10.1186/1753-6561-8-s5-s7 (2014).
- Needham, C. J., Bradford, J. R., Bulpitt, A. J., Care, M. A. & Westhead, D. R. Predicting the effect of missense mutations on protein function: analysis with Bayesian networks. *BMC bioinformatics* **7**, doi: 10.1186/1471-2105-7-405 (2006).
- Devanand, D. P. *et al.* MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease. *NeuroImage* **60**, 1622–1629, doi: 10.1016/j.neuroimage.2012.01.075 (2012).
- Reiman, E. M. & Jagust, W. J. Brain imaging in the study of Alzheimer's disease. *NeuroImage* **61**, 505–516, doi: 10.1016/j.neuroimage.2011.11.075 (2012).
- Cortes-Canteli, M., Mattei, L., Richards, A. T., Norris, E. H. & Strickland, S. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. *Neurobiology of aging* **36**, 608–617, doi: 10.1016/j.neurobiolaging.2014.10.030 (2015).
- Goto, M. *et al.* Entorhinal cortex volume measured with 3T MRI is positively correlated with the Wechsler Memory Scale-Revised logical/verbal memory score for healthy subjects. *Neuroradiology* **53**, 617–622, doi: 10.1007/s00234-011-0863-1 (2011).
- Mungas, D. *et al.* Dietary preference for sweet foods in patients with dementia. *Journal of the American Geriatrics Society* **38**, 999–1007 (1990).
- Cullen, P., Abid, F., Patel, A., Coope, B. & Ballard, C. Eating disorders in dementia. *International journal of geriatric psychiatry* **12**, 559–562 (1997).
- Barnes, M. J., Argyropoulos, G. & Bray, G. A. Preference for a high fat diet, but not hyperphagia following activation of mu opioid receptors is blocked in AgRP knockout mice. *Brain research* **1317**, 100–107, doi: 10.1016/j.brainres.2009.12.051 (2010).
- Luchsinger, J. A. & Gustafson, D. R. Adiposity, type 2 diabetes and Alzheimer's disease. *Journal of Alzheimer's disease: JAD* **16**, 693 (2009).

31. Groussard, M. *et al.* Musical and verbal semantic memory: Two distinct neural networks? *NeuroImage* **49**, 2764–2773, doi: 10.1016/j.neuroimage.2009.10.039 (2010).
32. Shinoura, N. *et al.* Right temporal lobe plays a role in verbal memory. *Neurological research* **33**, 734–738, doi: 10.1179/1743132811Y.0000000005 (2011).
33. Okereke, O. I. *et al.* Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. *Psychoneuroendocrinology* **33**, 455–461, doi: 10.1016/j.psyneuen.2008.01.002 (2008).
34. Tibshirani, R. Regression shrinkage and selection via the lasso. *Journal of the Royal Statistical Society. Series B (Methodological)*, 267–288 (1996).
35. Efron, B., Hastie, T., Johnstone, I. & Tibshirani, R. Least angle regression. *The Annals of statistics* **32**, 407–499 (2004).
36. Tsamardinos, I., Brown, L. E. & Aliferis, C. F. The max-min hill-climbing Bayesian network structure learning algorithm. *Machine Learning* **65**, 31–78, doi: 10.1007/s10994-006-6889-7 (2006).
37. Lauritzen, S. L. & Spiegelhalter, D. J. Local computations with probabilities on graphical structures and their application to expert systems. *Journal of the Royal Statistical Society. Series B (Methodological)*, 157–224 (1988).
38. Bradley, A. P. ROC curve equivalence using the Kolmogorov–Smirnov test. *Pattern Recognition Letters* **34**, 470–475, doi: 10.1016/j.patrec.2012.12.021 (2013).
39. Pinsky, P. F. Scaling of true and apparent ROC AUC with number of observations and number of variables. *Communications In Statistics-Simulation And Computation* **34**, 771–781, doi: 10.1081/sac-200068366 (2005).
40. Moradi, E. *et al.* Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects. *NeuroImage* **104**, 398–412, doi: 10.1016/j.neuroimage.2014.10.002 (2015).
41. Liu, H., Wei, C., He, H. & Liu, X. Evaluating Alzheimer's disease progression by modeling crosstalk network disruption. *Frontiers in Neuroscience* **9**, doi: 10.3389/fnins.2015.00523 (2015).
42. Casanova, R. *et al.* Alzheimer's Disease Risk Assessment Using Large-Scale Machine Learning Methods. *Plos One* **8**, doi: 10.1371/journal.pone.0077949 (2013).
43. Cheng, B., Liu, M., Zhang, D., Munsell, B. C. & Shen, D. Domain Transfer Learning for MCI Conversion Prediction. *IEEE transactions on bio-medical engineering* **62**, 1805–1817, doi: 10.1109/TBME.2015.2404809 (2015).
44. Yu, G., Liu, Y., Thung, K. H. & Shen, D. Multi-task linear programming discriminant analysis for the identification of progressive MCI individuals. *PLoS One* **9**, e96458, doi: 10.1371/journal.pone.0096458 (2014).

Acknowledgements

This study was supported by the National Natural Science Foundation of the People's Republic of China. (Nos 81273588 and 81473274). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann–La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Author Contributions

H.L., X.Z., H.J., H.H. and X.L. developed the model. H.L. do the computational work. H.L. wrote the manuscript. The data used in this manuscript is obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Liu, H. *et al.* A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease. *Sci. Rep.* **6**, 26712; doi: 10.1038/srep26712 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Consortia

The Alzheimer's Disease Neuroimaging Initiative

Michael W. Weiner², Paul Aisen³, Ronald Petersen⁴, Clifford R. Jack Jr.⁴, William Jagust⁵, John Q. Trojanowki⁶, Arthur W. Toga⁷, Laurel Beckett⁸, Robert C. Green⁹, Andrew J. Saykin¹⁰, John Morris¹¹, Leslie M. Shaw⁶, Zaven Khachaturian¹², Greg Sorensen¹³, Maria Carrillo¹⁴, Lew Kuller¹⁵, Marc Raichle¹¹, Steven Paul¹⁶, Peter Davies¹⁷, Howard Fillit¹⁸, Franz Hefti¹⁹, Davie Holtzman¹¹, M. Marcel Mesulam²⁰, William Potter²¹, Peter Snyder²², Tom Montine²³, Ronald G. Thomas³, Michael Donohue³, Sarah Walter³, Tamie Sather³, Gus Jiminez³, Archana B. Balasubramanian³, Jennifer Mason³, Iris Sim³, Danielle Harvey⁸, Matthew Bernstein⁴, Nick Fox²⁴, Paul Thompson²⁵, Norbert Schuff², Charles DeCarli⁸, Bret Borowski⁴, Jeff Gunter⁴, Matt Senjem⁴, Prashanthi Vemuri⁴, David Jones⁴, Kejal Kantarci⁴, Chad Ward⁴, Robert A. Koeppe²⁶, Norm Foster²⁷, Eric M. Reiman²⁸, Kewei Chen²⁸, Chet Mathis¹⁵, Susan Landau⁵, Nigel J. Cairns¹¹, Erin Householder¹¹, Lisa Taylor-Reinwald¹¹, Virginia Lee²⁵, Magdalena Korecka²⁵, Michal Figurski²⁵, Karen Crawford⁷, Scott Neu⁷, Tatiana M. Foroud¹⁰, Steven Potkin²⁹, Li Shen¹⁰, Kelley Faber¹⁰, Sungeun Kim¹⁰, Kwangsik Nho¹⁰, Lean Thai³, Richard Frank³¹, John Hsiao³², Jeffrey Kaye³³, Joseph Quinn³³, Lisa Silbert³³, Betty Lind³³, Raina Carter³³, Sara Dolen³³, Beau Ances¹¹, Maria Carroll¹¹, Mary L. Creech¹¹, Erin Franklin¹¹, Mark A. Mintun¹¹, Stacy Schneider¹¹, Angela Oliver¹¹, Lon S. Schneider⁷, Sonia Pawluczyk⁷, Mauricio Beccera⁷, Liberty Teodoro⁷, Bryan M. Spann⁷, James Brewer³, Helen Vanderswag³, Adam Fleisher³, Daniel Marson³⁴, Randall Griffith³⁴, David Clark³⁴, David Geldmacher³⁴, John Brockington³⁴, Erik Roberson³⁴, Marissa Natelson Love³⁴, Judith L. Heidebrink⁵, Joanne L. Lord⁵, Sara S. Mason⁴, Colleen S. Albers⁴, David Knopman⁴, Kris Johnson⁴, Hillel Grossman³⁵, Effie Mitsis³⁵, Raj C. Shah³⁶, Leyla deToledo-Morrell³⁶, Rachelle S. Doody³⁷, Javier Villanueva-Meyer³⁷, Munir Chowdhury³⁷, Susan Rountree³⁷, Mimi Dang³⁷, Ranjan Duara³⁸, Daniel Varon³⁸, Maria T. Greig³⁸, Peggy Roberts³⁸, Yaakov Stern³⁹, Lawrence S. Honig³⁹, Karen L. Bell³⁹, Marilyn Albert³⁰, Chiadi Onyike³⁰, Daniel D'Agostino II³⁰, Stephanie Kielb³⁰, James E. Galvin⁴⁰, Brittany Cerbone⁴⁰, Christina A. Michel⁴⁰, Dana M. Pogorelec⁴⁰, Henry Rusinek⁴⁰, Mony J de Leon⁴⁰, Lidia Glodzik⁴⁰, Susan De Santi⁴⁰, Kyle Womack⁴¹, Dana Mathews⁴¹, Mary Quiceno⁴¹, P. Murali Doraiswamy⁴², Jeffrey R. Petrella⁴², Salvador Borges-Neto⁴², Terence Z. Wong⁴², Edward Coleman⁴², Allan I. Levey⁴³, James J. Lah⁴³, Janet S. Cella⁴³, Jeffrey M. Burns⁴⁴, Russell H. Swerdlow⁴⁴, William M. Brooks⁴⁴, Steven E. Arnold⁶, Jason H. Karlawish⁶, David Wolk⁶, Christopher M. Clark⁶, Liana Apostolova²⁵, Kathleen Tingus²⁵, Ellen Woo²⁵, Daniel H.S. Silverman²⁵, Po H. Lu²⁵, George Bartzokis²⁵, Charles D. Smith⁴⁵, Greg Jicha⁴⁵, Peter Hardy⁴⁵, Partha Sinha⁴⁵, Elizabeth Oates⁴⁵, Gary Conrad⁴⁵, Neill R Graff-Radford⁴⁶, Francine Parfitt⁴⁶, Tracy Kendall⁴⁶, Heather Johnson⁴⁶, Oscar L. Lopez¹⁵, MaryAnn Oakley¹⁵, Donna M. Simpson¹⁵, Martin R. Farlow¹⁰, Ann Marie Hake¹⁰, Brandy R. Matthews¹⁰, Jared R. Brosch¹⁰, Scott Herring¹⁰, Cynthia Hunt¹⁰, Anton P. Porsteinsson⁴⁷, Bonnie S. Goldstein⁴⁷, Kim Martin⁴⁷, Kelly M. Makino⁴⁷, M. Saleem Ismail⁴⁷, Connie Brand⁴⁷, Ruth A. Mulnard⁴⁷, Gaby Thai⁴⁷, Catherine Mc-Adams-Ortiz⁴⁷, Christopher H. van Dyck⁴⁸, Richard E. Carson⁴⁸, Martha G. MacAvoy⁴⁸, Pradeep Varma⁴⁸, Howard Chertkow⁴⁹, Howard Bergman⁴⁹, Chris Hosein⁴⁹, Sandra Black⁵⁰, Bojana Stefanovic⁵⁰, Curtis Caldwell⁵⁰, Ging-Yuek Robin Hsiung⁵¹, Howard Feldman⁵¹, Benita Mudge⁵¹, Michele Assaly⁵¹, Elizabeth Finger⁵², Stephen Pasternack⁵², Irina Rachisky⁵², Dick Trost⁵², Andrew Kertesz^{52,61}, Charles Bernick⁵³, Donna Munic⁵³, Kristine Lipowski²⁰, MASandra Weintraub²⁰, Borna Bonakdarpour²⁰, Diana Kerwin²⁰, Chuang-Kuo Wu²⁰, Nancy Johnson²⁰, Carl Sadowsky⁵⁴, Teresa Villena⁵⁴, Raymond Scott Turner⁵⁵, Kathleen Johnson⁵⁵, Brigid Reynolds⁵⁵, Reisa A. Sperling⁹, Keith A. Johnson⁹, Gad Marshall⁹, Jerome Yesavage⁵⁶, Joy L. Taylor⁵⁶, Barton Lane⁵⁶, Allyson Rosen⁵⁶, Jared Tinklenberg⁵⁶, Marwan N. Sabbagh²⁸, Christine M. Belden²⁸, Sandra A. Jacobson²⁸, Sherye A. Sirrel²⁸, Neil Kowall⁵⁷, Ronald Killiany⁵⁷, Andrew E. Budson⁵⁷, Alexander Norbash⁵⁷, Patricia Lynn Johnson⁵⁷, Thomas O. Obisesan⁵⁸, Saba Wolday⁵⁸, Joanne Allard⁵⁸, Alan Lerner⁵⁹, Paula Ogrocki⁵⁹, Curtis Tatsuoaka⁵⁹, Parianne Fatica⁵⁹, Evan Fletcher⁸, Pauline Maillard⁸, John Olichney⁸, Owen Carmichael⁸, Smita Kittur⁶⁰, Michael Borrie⁶¹, T-Y Lee⁶¹, Rob Bartha⁶¹, Sterling Johnson⁶¹, Sanjay Asthana⁶¹, Cynthia M. Carlsson⁶¹, Adrian Preda²⁹, Dana Nguyen²⁹, Pierre Tariot²⁸, Anna Burke²⁸, Nadira Trncic²⁸, Adam Fleisher²⁸, Stephanie Reeder²⁸, Vernice Bates⁶², Horacio Capote⁶², Michelle Rainka⁶², Douglas W. Scharre⁶³, Maria Kataki⁶³, Anahita Adeli⁶³, Earl A. Zimmerman⁶⁴, Dzintra Celmins⁶⁴, Alice D. Brown⁶⁴, Godfrey D. Pearlson⁶⁵, Karen Blank⁶⁵, Karen Anderson⁶⁵, Laura A. Flashman⁶⁶, Marc Seltzer⁶⁶, Mary L. Hynes⁶⁶, Robert B. Santulli⁶⁶, Kaycee M. Sink⁶⁷, Leslie Gordineer⁶⁷, Jeff D. Williamson⁶⁷, Pradeep Garg⁶⁷, Franklin Watkins⁶⁷,

Brian R. Ott²², Henry Querfurth²², Geoffrey Tremont²², Stephen Salloway²², Paul Malloy²², Stephen Correia²², Howard J. Rosen², Bruce L. Miller², David Perry², Jacobo Mintzer⁶⁸, Kenneth Spicer⁶⁸, David Bachman⁶⁸, Elizabeth Finger⁶¹, Stephen Pasternak⁶¹, Irina Rachinsky⁶¹, John Rogers⁶¹, Dick Drost⁶¹, Nunzio Pomara⁶⁹, Raymundo Hernando⁶⁹, Antero Sarrae⁶⁹, Susan K. Schultz⁷⁰, Laura L. Boles Ponto⁷⁰, Hyungsub Shim⁷⁰, Karen Ekstam Smith⁷⁰, Norman Relkin¹⁶, Gloria Chaing¹⁶, Michael Lin¹⁶, Lisa Ravdin¹⁶, Amanda Smith⁷¹, Balebail Ashok Raj⁷¹, Kristin Fargher⁷¹.

²UC San Francisco, San Francisco, CA 94107, USA. ³UC San Diego, La Jolla, CA 92093 USA. ⁴Mayo Clinic, Rochester, MN USA. ⁵UC Berkeley, Berkeley, San Francisco, USA. ⁶University of Pennsylvania, Philadelphia, PA 19104, USA. ⁷USC, Los Angeles, CA 90032, USA. ⁸UC Davis, Sacramento, CA, USA. ⁹Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02215 USA. ¹⁰Indiana University, Bloomington, IN 47405 USA. ¹¹Washington University St. Louis, MO 63110 USA. ¹²Prevent Alzheimer's Disease 2020, Rockville, MD 20850 USA. ¹³Siemens, Erlangen, Germany. ¹⁴Alzheimer's Association, Chicago, IL 60631 USA. ¹⁵University of Pittsburg, Pittsburgh, PA 15213 USA. ¹⁶Cornell University, Ithaca, NY 14853 USA. ¹⁷Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461 USA. ¹⁸AD Drug Discovery Foundation, New York, NY 10019 USA. ¹⁹Acumen Pharmaceuticals, Livermore, CA 94551 USA. ²⁰Northwestern University, Chicago, IL 60611 USA. ²¹National Institute of Mental Health, Bethesda, MD 20892 USA. ²²Brown University, Providence, RI 02912 USA. ²³University of Washington, Seattle, WA 98195, USA. ²⁴University of London, London, UK. ²⁵UCLA, Torrance, CA 90509 USA. ²⁶University of Michigan, Ann Arbor, MI, 48109-2800, USA. ²⁷University of Utah, Salt Lake City, UT, 84112, USA. ²⁸Banner Alzheimer's Institute, Phoenix, AZ 85006, USA. ²⁹UUC Irvine, Orange, CA 92868 USA. ³⁰Johns Hopkins University, Baltimore, MD 21205 USA. ³¹Richard Frank Consulting, USA. ³²National Institute on Aging, Baltimore, Maryland, USA. ³³Oregon Health and Science University, Portland, OR 97239 USA. ³⁴University of Alabama, Birmingham, AL USA. ³⁵Mount Sinai School of Medicine, New York, NY USA. ³⁶Rush University Medical Center, Chicago, IL 60612, USA. ³⁷Baylor College of Medicine, Houston, TX, USA. ³⁸Wien Center, Miami Beach, FL 33140 USA. ³⁹Columbia University Medical Center, New York, NY USA. ⁴⁰New York University, New York, NY USA. ⁴¹University of Texas Southwestern Medical School, Galveston, TX 77555 USA. ⁴²Duke University Medical Center, Durham, NC USA. ⁴³Emory University, Atlanta, GA, 30307, USA. ⁴⁴University of Kansas Medical Center, Kansas City, Kansas, USA. ⁴⁵University of Kentucky, Lexington, KY, USA. ⁴⁶Mayo Clinic, Jacksonville, Florida, USA. ⁴⁷University of Rochester Medical Center, Rochester, NY 14642, USA. ⁴⁸Yale University School of Medicine, New Haven, CT, USA. ⁴⁹McGill Univ. Montreal-Jewish General Hospital, Montreal, PQ H3A 2A7, Canada. ⁵⁰Sunnybrook Health Sciences, Toronto, ON, Canada. ⁵¹U.B.C. Clinic for AD & Related Disorders, Vancouver, BC Canada. ⁵²Cognitive Neurology - St. Joseph's, London, ON, Canada. ⁵³Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106 USA. ⁵⁴Premiere Research Inst (Palm Beach Neurology), W Palm Beach, FL USA. ⁵⁵Georgetown University Medical Center, Washington, DC 20007 USA. ⁵⁶Stanford University, Stanford, CA 94305 USA. ⁵⁷Boston University, Boston, Massachusetts USA. ⁵⁸Howard University, Washington, DC 20059 USA. ⁵⁹Case Western Reserve University, Cleveland, OH 44106 USA. ⁶⁰Neurological Care of CNY, Liverpool, NY 13088 USA. ⁶¹St. Joseph's Health Care, London, ON N6A 4H1, Canada. ⁶²Dent Neurologic Institute, Amherst, NY 14226 USA. ⁶³Ohio State University, Columbus, OH 43210 USA. ⁶⁴Albany Medical College, Albany, NY 12208 USA. ⁶⁵Hartford Hospital Olin Neuropsychiatry Research Center, Hartford, CT 06114 USA. ⁶⁶Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. ⁶⁷Wake Forest University Health Sciences, Winston-Salem, NC, USA. ⁶⁸Medical University South Carolina, Charleston, SC 29425 USA. ⁶⁹Nathan Kline Institute, Orangeburg, NY USA. ⁷⁰University of Iowa College of Medicine, Iowa City, IA 52242 USA. ⁷¹University of South Florida: USF Health Byrd Alzheimer's Institute, Tampa, FL 33613 USA.